BioNTech Results Presentation Deck
4 BNT411: initiated FIH Phase 1 trial for our TLR7 agonist in July 2020
BNT411 is an intravenously administered small molecule TLR7 (toll-like receptor 7) agonist
Engineered for high potency and high TLR7 receptor-selectivity at the therapeutically active dose range
Activation of both adaptive and innate immune system has been observed, in particular in combination with cytotoxic
therapies and CPIs
●
●
●
●
●
16
Type 1 interferon-dominated release of cytokines and chemokines and potent stimulation of antigen-specific CD8+ T
cells, B cells and innate immune cells such as NK cells and macrophages
Expected to have therapeutic potential across various solid tumor indications
Phase 1/2a clinical trial as a mono and combination therapy initiated in July 2020
Study design:
Phase 1/2a, first-in-human, open-label, dose-escalation trial
Evaluation of safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT411 as
a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and
etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer (ES-SCLC)
Enrollment: ~60 participants
●
BIONTECHView entire presentation